Related Experiment Video
Updated: Apr 19, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Updates and trends in the treatment of major depressive disorder
George I Papakostas1, Dawn F Ionescu
1Massachusetts General Hospital, Clinical Trials Network and Institute and Depression Clinical and Research Program, 1 Bowdoin Square, 6th Fl, Boston, MA 02114 gpapakostas@partners.org.
Abstract:
Mental illness accounts for 7.4% of the total disease burden worldwide-more than HIV/AIDS, tuberculosis, or diabetes-making it the leading cause of years lost to disability. Depressive disorders make up 40.5% of that disability, the most of all mental illnesses. Despite the devastating global effects of depression, a report on approval trends by the US Food and Drug Administration (FDA) found that new molecular entities (NMEs) approved for targeting psychiatric illness peaked in the 1960s and have been declining since.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Overview
Depression: Overview
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Depressive Disorders: MDD and Dysthymia

